BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company...

BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide,
Company Data Indicates

ATLANTA, June 29 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an
implantable biological medical device and cardiovascular tissue processing
company, today announced that, according to company data, CryoLife's
BioGlue(R) Surgical Adhesive has been used in more than 500,000 surgical
procedures throughout the world since its introduction into the international
market in 1998 and in the United States in 2001. BioGlue is a leading
surgical adhesive used in cardiovascular surgeries worldwide.

"I have been using BioGlue since its market introduction almost 10 years ago,"
said Dr. John W. Fehrenbacher, Methodist Hospital, Indianapolis, Ind. "I have
utilized BioGlue in over 1,000 patients undergoing a variety of cardiac
procedures including valve replacements, aneurysm repair, and aortic
dissection repair. I find that BioGlue is safe, easy to use, and because of
its effectiveness at reducing anastomotic bleeding, has allowed me to change
the way I perform many of my aortic aneurysm procedures."

A two-component adhesive, BioGlue creates a flexible, mechanical seal,
independent of the body's clotting mechanism. BioGlue comes in a
self-contained, disposable syringe that is available in 2mL, 5mL, and 10mL
volumes. Ergonomically designed, the delivery system allows for simple
preparation and ease of use.

"The use of BioGlue has continued to grow as surgeons around the globe have
experienced its highly effective sealing properties during complex
procedures," said Steven G. Anderson, president and CEO of CryoLife. "We
anticipate the continued adoption of BioGlue as an essential component of the
surgical toolkit, particularly as it is approved for additional indications."

BioGlue is currently approved by the U.S. Food and Drug Administration as an
adjunct to sutures and staples for use in adult patients in open surgical
repair of large vessels. It is used most commonly in the U.S. for complex
cardiovascular procedures involving aortic aneurysms, valve replacements and
aortic dissections, as well as peripheral vascular procedures, such as carotid
endarterectomy, and arteriovenous access.

In the international market, BioGlue is indicated for use in cardiac and
vascular procedures as well as for repair of other soft tissues, including
pulmonary, genitourinary, dural, alimentary (esophageal, gastrointestinal, and
colorectal), and other abdominal tissues (pancreatic, splenic, hepatic,
biliary). It is also used in the fixation of surgical meshes in hernia
repair.

BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community
for periosteal fixation following endoscopic browplasty (brow lift) in
reconstructive plastic surgery and is distributed by a third party for this
indication.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiac and vascular surgeries
throughout the U.S. and Canada. The Company's CryoValve(R) SG pulmonary human
heart valve, processed using CryoLife's proprietary SynerGraft(R) technology,
has FDA 510(k) clearance for the replacement of diseased, damaged, malformed
or malfunctioning native pulmonary valves. The Company's BioGlue(R) Surgical
Adhesive is FDA approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is also CE marked
in the European Community and approved in Canada and Australia for use in soft
tissue repair. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the
European Community for periosteal fixation following endoscopic browplasty
(brow lift) in reconstructive plastic surgery and is distributed by a third
party for this indication. CryoLife distributes HemoStase(TM), a hemostatic
agent, in much of the U.S. for use in cardiac and vascular surgery and in the
European Community and Canada for cardiac, vascular, and general surgery,
subject to certain exclusions.

Statements made in this press release that look forward in time or that
express management's beliefs, expectations or hopes are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include those regarding BioGlue's anticipated
continued adoption and approval for additional indications. These risks and
uncertainties include that we are significantly dependent on revenues from
BioGlue and there are a variety of risks affecting BioGlue; the risk of not
obtaining additional approvals on a timely basis or at all due to testing
results proving disappointing, additional costs, and requirements or trials
that might be imposed; the risk that adoption by doctors can be negatively
impacted by numerous factors including adverse publicity and competing
products; that uncertainties related to patents and protection of proprietary
technology may adversely affect the value of our intellectual property; we may
not be successful in obtaining necessary clinical results and additional
regulatory approvals for products and services in development, and our new
products and services may not achieve market acceptance; and that rapid
technological change could cause our services and products to become obsolete.
These risks and uncertainties include the risk factors detailed in our
Securities and Exchange Commission filings, including our Form 10-K filing for
the year ended December 31, 2008, our most recent Form 10-Q, and the Company's
other SEC filings. The Company does not undertake to update its
forward-looking statements.

For additional information about the Company, visit CryoLife's Web Site:
http://www.cryolife.com.
CONTACT:
D. Ashley Lee Katie Brazel
Executive Vice President, Chief Financial Fleishman Hillard
Officer and Chief Operating Officer Phone: 404-739-0150
Phone: 770-419-3355

SOURCE CryoLife, Inc.

D. Ashley Lee, Executive Vice President, Chief Financial Officer and Chief
Operating Officer, CryoLife, Inc., +1-770-419-3355; or Katie Brazel, Fleishman
Hillard, +1-404-739-0150